Prothena Shares Are Trading Higher After the Phase IIb Prasinezumab Study Showed Potential in Early Parkinson's Disease.
Prothena Shares Are Trading Higher After the Phase IIb Prasinezumab Study Showed Potential in Early Parkinson's Disease.
Prothena的股票在IIb期Prasinezumab研究顯示早期帕金森病的潛力後上漲。
Prothena Shares Are Trading Higher After the Phase IIb Prasinezumab Study Showed Potential in Early Parkinson's Disease.
Prothena的股票在IIb期Prasinezumab研究顯示早期帕金森病的潛力後上漲。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間